NasdaqGM - Delayed Quote • USD
KalVista Pharmaceuticals, Inc. (KALV)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 4:02 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Benjamin L. Palleiko | CEO & Director | 707.1k | -- | 1966 |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer | 640.23k | -- | 1964 |
| Dr. Edward P. Feener Ph.D. | Chief Scientific Officer | 506k | -- | 1960 |
| Mr. Ryan Baker | Head of Investor Relations | -- | -- | -- |
| Mr. Brian Krex J.D. | General Counsel | -- | -- | 1968 |
| Jarrod Aldom | Vice President of Corporate Communications | -- | -- | -- |
| Ms. Rachel M. Morten | Senior Vice President of Regulatory Affairs & QA | -- | -- | -- |
| Dr. Michael D. Smith Pharm.D. | Senior Vice President of Development | -- | -- | 1980 |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer | -- | -- | 1973 |
| Ms. Nicole Sweeny | Chief Commercial Officer | -- | -- | 1976 |
KalVista Pharmaceuticals, Inc.
55 Cambridge Parkway
Suite 901 East
Cambridge, MA 02142
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 118
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
Corporate Governance
KalVista Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 5; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 11, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 07, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 16, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 14, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 13, 20248-K: Corporate Changes & Voting MattersSee Full Filing
Upcoming Events
Jul 05, 2024 - Jul 09, 2024
KalVista Pharmaceuticals, Inc. Earnings Call
Related Tickers
PHVS Pharvaris N.V.
18.42
-13.11%
NUVL Nuvalent, Inc.
63.06
-1.85%
ATXS Astria Therapeutics, Inc.
10.54
-0.09%
PHAT Phathom Pharmaceuticals, Inc.
9.48
-3.27%
IMTX Immatics N.V.
10.26
+0.29%
LYRA Lyra Therapeutics, Inc.
5.39
-0.28%
SPRY ARS Pharmaceuticals, Inc.
8.44
-6.84%
PTCT PTC Therapeutics, Inc.
24.69
-1.87%
LBPH Longboard Pharmaceuticals, Inc.
18.01
+5.94%
IMCR Immunocore Holdings plc
54.74
+0.29%